Endometrial cancer is the most common female genital tract malignancy in the United States. Type I endometrial cancer is usually diagnosed at an early stage, and has a good prognosis. Type II is very aggressive, and is responsible for most uterine cancer relapses and deaths. Uterine serous adenocarcinomas (USC) constitute the majority of Type II variants. They have a higher propensity for lymph node and distant metastases. They are frequently aneuploid and associated with p53 mutations. erbB2 overexpression in USC has been described. The incidence, which is higher in African Americans, ranges from 18–80%. erbB2 overexpression was found to be associated with higher stage, chemoresistance, and worse survival. Trastuzumab a humanized mAb was approved by the FDA for treatment of breast cancers that overexpress erbB2 in combination with standard chemotherapy. Evidence of trastuzumab activity in USC has been reported in vitro, as well as in case reports of advanced and recurrent cases. Promising results were obtained in these heavily pretreated patients either with trastuzumab alone or in combination with chemotherapy. This supports the hypothesis that trastuzumab may very well be an attractive and viable treatment option for advanced stage USC tumors that overexpress the erbB2, and is worthy of further study. 1. Endometrial Cancer Endometrial cancer is the most common female genital tract malignancy in the United States, with an incidence of 40100 new cases and 7470 deaths annually [1]. Type I endometrial cancer, which has an endometrioid histology, is associated with obesity, estrogen excess, and is heralded by endometrial hyperplasia. It is usually diagnosed at an early stage and has a good prognosis. On the other hand, Type II endometrial cancer is a very aggressive variant of the disease and is responsible for about 50% of all uterine cancer relapses and most deaths [2]. 2. Uterine Serous Cancer Uterine serous adenocarcinomas (USC) constitute the majority of Type II variants, and about 10% of all endometrial cancers [3]. USC has a higher propensity for lymphovascular invasion, and intraperitoneal as well as extraabdominal spread, than endometrioid carcinoma. It also has a significantly greater incidence of pelvic and para-aortic lymph node metastases [4]. At the time of presentation, approximately 60 to 70 percent of women with USC will have-disease spread outside of the uterus [3]. Overall 1-year-, 2-year-, and 5-year-survival in USC is 84%, 71%, and 54%, respectively. This is compared to a respective overall survival of 94%, 89%, and 80% in
References
[1]
A. Jemal, R. Siegel, J. Xu, and E. Ward, “Cancer statistics, 2010,” CA Cancer Journal for Clinicians, vol. 60, no. 5, pp. 277–300, 2010.
[2]
P. E. Schwartz, “The management of serous papillary uterine cancer,” Current Opinion in Oncology, vol. 18, no. 5, pp. 494–499, 2006.
[3]
B. M. Slomovitz, T. W. Burke, P. J. Eifel et al., “Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases,” Gynecologic Oncology, vol. 91, no. 3, pp. 463–469, 2003.
[4]
F. Amant, P. Moerman, P. Neven, D. Timmerman, E. Van Limbergen, and I. Vergote, “Endometrial cancer,” Lancet, vol. 366, no. 9484, pp. 491–505, 2005.
[5]
W. T. Creasman, F. Odicino, P. Maisonneuve et al., “Carcinoma of the corpus uteri,” Journal of Epidemiology and Biostatistics, vol. 6, no. 1, pp. 47–86, 2001.
[6]
M. G. Kelly, D. M. O'Malley, P. Hui et al., “Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy,” Gynecologic Oncology, vol. 98, no. 3, pp. 353–359, 2005.
[7]
B. A. Goff, “Uterine papillary serous carcinoma: what have we learned over the past quarter century?” Gynecologic Oncology, vol. 98, no. 3, pp. 341–343, 2005.
[8]
C. A. Hamilton, W. S. Liou, K. Osann et al., “Impact of adjuvant therapy on survival of patients with early-stage uterine papillary serous carcinoma,” International Journal of Radiation Oncology Biology Physics, vol. 63, no. 3, pp. 839–844, 2005.
[9]
J. D. Martin, B. Gilks, and P. Lim, “Papillary serous carcinoma—a less radio-sensitive subtype of endometrial cancer,” Gynecologic Oncology, vol. 98, no. 2, pp. 299–303, 2005.
[10]
K. M. Alektiar, V. Makker, N. R. Abu-Rustum et al., “Concurrent carboplatin/paclitaxel and intravaginal radiation in surgical stage I-II serous endometrial cancer,” Gynecologic Oncology, vol. 112, no. 1, pp. 142–145, 2009.
[11]
S. Acharya, M. L. Hensley, A. C. Montag, and G. F. Fleming, “Rare uterine cancers,” Lancet Oncology, vol. 6, no. 12, pp. 961–971, 2005, Erratum: Lancet Oncology, vol. 7, no. 2, p. 105, 2005.
[12]
A. D. Santin, S. Bellone, S. Van Stedum et al., “Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma,” Cancer, vol. 104, no. 7, pp. 1391–1397, 2005.
[13]
S. F. Lax, “Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification,” Virchows Archiv, vol. 444, no. 3, pp. 213–223, 2004.
[14]
A. D. Santin, S. Bellone, M. Gokden et al., “Overexpression of HER-2/neu in uterine serous papillary cancer,” Clinical Cancer Research, vol. 8, no. 5, pp. 1271–1279, 2002.
[15]
A. D. Santin, F. Zhan, S. Cane et al., “Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy,” British Journal of Cancer, vol. 92, no. 8, pp. 1561–1573, 2005.
[16]
F. E. Odicino, E. Bignotti, E. Rossi et al., “HER-2/neu overexpression and amplification in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry, real-time reverse transcription-polymerase chain reaction, and fluorescence in situ hybridization,” International Journal of Gynecological Cancer, vol. 18, no. 1, pp. 14–21, 2008.
[17]
T. P. Díaz-Montes, H. Ji, A. E. Smith Sehdev et al., “Clinical significance of Her-2/neu overexpression in uterine serous carcinoma,” Gynecologic Oncology, vol. 100, no. 1, pp. 139–144, 2006.
[18]
A. D. Santin, S. Bellone, E. R. Siegel et al., “Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer,” American Journal of Obstetrics and Gynecology, vol. 192, no. 3, pp. 813–818, 2005.
[19]
A. D. Santin, S. Bellone, S. Van Stedum et al., “Determination of HER2/neu status in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry and fluorescence in situ hybridization,” Gynecologic Oncology, vol. 98, no. 1, pp. 24–30, 2005.
[20]
T. A. Grushko, V. L. Filiaci, A. J. Mundt, K. Ridderstr？le, O. I. Olopade, and G. F. Fleming, “An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a gynecologic oncology group study,” Gynecologic Oncology, vol. 108, no. 1, pp. 3–9, 2008.
[21]
Y. Yarden and M. X. Sliwkowski, “Untangling the ErbB signalling network,” Nature Reviews Molecular Cell Biology, vol. 2, no. 2, pp. 127–137, 2001.
[22]
D. J. Hetzel, T. O. Wilson, G. L. Keeney, P. C. Roche, S. S. Cha, and K. C. Podratz, “HER-2/neu expression: a major prognostic factor in endometrial cancer,” Gynecologic Oncology, vol. 47, no. 2, pp. 179–185, 1992.
[23]
A. Berchuck, A. Kamel, R. Whitaker et al., “Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer,” Cancer Research, vol. 50, no. 13, pp. 4087–4091, 1990.
[24]
A. Berchuck, G. Rodriguez, R. B. Kinney et al., “Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease,” American Journal of Obstetrics and Gynecology, vol. 164, no. 1, part 1, pp. 15–21, 1991.
[25]
D. J. Slamon, G. M. Clark, S. G. Wong, W. J. Levin, A. Ullrich, and W. L. McGuire, “Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene,” Science, vol. 235, no. 4785, pp. 177–182, 1987.
[26]
R. A. Clynes, T. L. Towers, L. G. Presta, and J. V. Ravetch, “Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets,” Nature Medicine, vol. 6, no. 4, pp. 443–446, 2000.
[27]
R. Gennari, S. Menard, F. Fagnoni et al., “Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2,” Clinical Cancer Research, vol. 10, no. 17, pp. 5650–5655, 2004.
[28]
L. Arnould, M. Gelly, F. Penault-Llorca et al., “Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?” British Journal of Cancer, vol. 94, no. 2, pp. 259–267, 2006.
[29]
K. El-Sahwi, S. Bellone, E. Cocco et al., “In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma,” British Journal of Cancer, vol. 102, no. 1, pp. 134–143, 2010.
[30]
D. J. Slamon, B. Leyland-Jones, S. Shak et al., “Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2,” New England Journal of Medicine, vol. 344, no. 11, pp. 783–792, 2001.
[31]
M. J. Piccart-Gebhart, M. Procter, B. Leyland-Jones et al., “Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer,” New England Journal of Medicine, vol. 353, no. 16, pp. 1659–1672, 2005.
[32]
I. N. Olver, “Trastuzumab as the laed monoclonal antibody in advanced breast cancer: choosing which patient and when,” Future Oncology, vol. 4, no. 1, pp. 125–131, 2008.
[33]
E. H. Romond, E. A. Perez, J. Bryant et al., “Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer,” New England Journal of Medicine, vol. 353, no. 16, pp. 1673–1684, 2005.
[34]
R. Mass, “The role of HER-2 expression in predicting response to therapy in breast cancer,” Seminars in Oncology, vol. 27, no. 6, supplement 11, pp. 46–52, 2000.
[35]
G. F. Fleming, M. W. Sill, K. M. Darcy et al., “Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: A Gynecologic Oncology Group study,” Gynecologic Oncology, vol. 116, no. 1, pp. 15–20, 2010.
[36]
A. D. Santin, “Letter to the Editor referring to the manuscript entitled: "phase II trial of trastuzumab in women with advanced or recurrent HER-positive endometrial carcinoma: A Gynecologic Oncology Group Study" recently reported by Fleming,” Gynecologic Oncology, vol. 118, no. 1, pp. 95–96, 2010.
[37]
A. D. Santin, S. Bellone, J. J. Roman, J. K. McKenney, and S. Pecorelli, “Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu,” International Journal of Gynecology and Obstetrics, vol. 102, no. 2, pp. 128–131, 2008.
[38]
E. Jewell, A. A. Secord, T. Brotherton, and A. Berchuck, “Use of trastuzumab in the treatment of metastatic endometrial cancer,” International Journal of Gynecological Cancer, vol. 16, no. 3, pp. 1370–1373, 2006.
[39]
J. A. Villella, S. Cohen, D. H. Smith, H. Hibshoosh, and D. Hershman, “HER-2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications,” International Journal of Gynecological Cancer, vol. 16, no. 5, pp. 1897–1902, 2006.
[40]
A. D. Santin, “HER2/neu overexpression: has the Achilles' heel of uterine serous papillary carcinoma been exposed?” Gynecologic Oncology, vol. 88, no. 3, pp. 263–265, 2003.
